Three in four do not meet American guideline recommendations
By Lori Solomon HealthDay Reporter
FRIDAY, July 7, 2023 (HealthDay News) — Most adults with coronary artery disease (CAD) do not meet low-density lipoprotein cholesterol (LDL-C) targets, according to a research letter published in the July 3 issue of the Journal of the American Medical Association.
Rahul Aggarwal, M.D., from Brigham and Women s Hospital in Boston, and colleagues used data from the National Health and Nutrition Examination Survey (January 2015 to March 2020) to assess lipid control among 25,531 U.S. adults (â¥20 years) with reported CAD.
The researchers found that among adults with reported CAD, 67.9 percent were receiving statin therapy and 6.4 percent were receiving ezetimibe. Age-adjusted mean LDL-C was 94.4 mg/dL, with 73.5 percent of participants having an LDL-C level â¥70 mg/dL. Among adults with reported CAD receiving statin therapy, 4.2 percent also reported receiving ezetimibe. The age-adjusted mean LDL-C level among adults with CAD receiving statin therapy was 82.2 mg/dL, with 65.2 percent having an LDL-C level â¥70 mg/dL. Among participants reporting CAD but not receiving statin therapy, 10.9 percent were receiving ezetimibe. The age-adjusted mean LDL-C level was 120.4 mg/dL, with 91.0 percent having an LDL-C level â¥70 mg/dL.
“Achievement of guideline-directed targets for LDL-C among adults with reported CAD was low, with almost three in four participants not meeting American College of Cardiology/American Heart Association guideline targets and nine in 10 not meeting European Society of Cardiology guideline targets,” the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2023 HealthDay. All rights reserved.
